↓ Skip to main content

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

Overview of attention for article published in Arthritis Research & Therapy, September 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
4 X users

Citations

dimensions_citation
81 Dimensions

Readers on

mendeley
72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
Published in
Arthritis Research & Therapy, September 2013
DOI 10.1186/ar4313
Pubmed ID
Authors

Jens Thiel, Fabian Hässler, Ulrich Salzer, Reinhard E Voll, Nils Venhoff

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is part of antineutrophil cytoplasmic antibodies (ANCAs)-associated vasculitides. In EGPA small-vessel vasculitis is associated with eosinophilia and asthma. About 40% of EGPA patients are ANCA-positive, suggesting a role for B cells in the pathogenesis of EGPA. B cell-depleting therapy with rituximab (RTX) can be effective in ANCA-positive EGPA, but very few patients have been published to date. The role of RTX in the treatment of ANCA-negative EGPA is unclear.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
United States 1 1%
Germany 1 1%
Italy 1 1%
Unknown 68 94%

Demographic breakdown

Readers by professional status Count As %
Other 14 19%
Researcher 12 17%
Student > Master 10 14%
Student > Doctoral Student 5 7%
Student > Bachelor 4 6%
Other 13 18%
Unknown 14 19%
Readers by discipline Count As %
Medicine and Dentistry 44 61%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Biochemistry, Genetics and Molecular Biology 2 3%
Nursing and Health Professions 2 3%
Mathematics 1 1%
Other 4 6%
Unknown 17 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 March 2015.
All research outputs
#16,047,334
of 25,373,627 outputs
Outputs from Arthritis Research & Therapy
#2,337
of 3,381 outputs
Outputs of similar age
#123,237
of 215,075 outputs
Outputs of similar age from Arthritis Research & Therapy
#48
of 67 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,381 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 215,075 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.